share_log

Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $14

Benzinga ·  Mar 18 10:07

Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 383

Recommended

Write a comment